Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries

The COVID-19 pandemic sparked the development of novel anti-viral drugs that have shown to be effective in reducing both fatality and hospitalization rates in patients with elevated risk for COVID-19 related morbidity or mortality. Currently, nirmatrelvir/ritonavir (Paxlovid™) fixed-dose combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Dallas J., Bi, Huichang, Hamman, Josias, Ma, Xiaochao, Mitchell, Constance, Nyirenda, Kumbukani, Monera-Penduka, Tsitsi, Oketch-Rabah, Hellen, Paine, Mary F., Pettit, Syril, Pheiffer, Wihan, Van Breemen, Richard B., Embry, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368978/
https://www.ncbi.nlm.nih.gov/pubmed/37502215
http://dx.doi.org/10.3389/fphar.2023.1210579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368978/
https://www.ncbi.nlm.nih.gov/pubmed/37502215
http://dx.doi.org/10.3389/fphar.2023.1210579

Ejemplares similares